BVD’s pipeline comprises Ulixertinib (BVD-523), a small-molecule ERK1/2 kinase inhibitor in ... across a wide variety of tumor types 1, 2. These antibodies have also shown activity when deployed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback